Much less is known on the effects of glucagon-like peptide-1 (GLP-1) receptor agonists, and there are no data on newer medications containing GLP-1 receptor agonists in combination with other incretin hormones on the pseudo-hypogonadism of obesity (39). Here, GLP1R is linked to obesity disorder.